Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Source: SeekingAlpha
2025-09-24 08:05:58 ET
More on Acadia Pharma, Soleno Therapeutics
- Soleno Therapeutics: Patient Death Unrelated To Vykat, But Safety Concerns May Undermine Launch
- ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- Soleno drops on death of patient treated with Vykat XR
- Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake
Read the full article on Seeking Alpha
For further details see:
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
-1.34% G/L:
$21.025 Last:
573,736 Volume:
$21.41 Open:
ACAD Latest News
March 12, 2026 04:05:00 pm
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 03, 2026 04:05:00 pm
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
ACAD Stock Data
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
